Back to search
FDAFDA · Food and drugs·Recall number D-0299-2022

Veklury (remdesivir) for injection, 100 mg/vial, Single-Dose Vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, NDC 61958-2901-2

Published January 5, 2022 · Recall initiated: December 3, 2021

Summary

FDA records drug Class I recall D-0299-2022, published January 5, 2022 and initiated December 3, 2021. Recalling firm: Gilead Sciences, Inc.; Status: Terminated; Reported quantity: 53,473 vials; Lot: Lots: 2141001-1A, 2141002-1A, Exp. 01/2024. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Presence of Particulate Matter: investigation into a customer complaint confirmed the presence of glass particulates.

What to do

Voluntary: Firm initiated · Press Release

Get an email if VEKLURY has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
VEKLURY
Manufacturer
Gilead Sciences, Inc.
Distributor
Nationwide in the USA
Lot
Lots: 2141001-1A, 2141002-1A, Exp. 01/2024
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Veklury (remdesivir) for injection, 100 mg/vial, Single-Dose Vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, NDC 61958-2901-2 recalled?

Yes. FDA published recall D-0299-2022 on January 5, 2022. Reported hazard: Presence of Particulate Matter: investigation into a customer complaint confirmed the presence of glass particulates.

What should I do if I have this product?

Voluntary: Firm initiated · Press Release

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: VEKLURY.